Adam Zuzelski, MD
Family Medicine · Manhattan, KSNPI 1891351136
Payments from drug & device makers
Across 334 payments — averaging $16.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$945
- AbbVie$941
- Novo Nordisk$674
- Lilly USA, LLC$627
- AstraZeneca$566
- Amgen$411
- plus $1K from 26 others
What the payments were for
- Food & beverage$5,528100%
- Education$250%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 68 | $945 |
| AbbVie | 56 | $941 |
| Novo Nordisk | 44 | $674 |
| Lilly USA, LLC | 39 | $627 |
| AstraZeneca | 17 | $566 |
| Amgen | 34 | $411 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 15 | $236 |
| GSK | 12 | $193 |
| Abbott | 6 | $126 |
| Merck | 5 | $90 |
| Johnson & Johnson | 4 | $71 |
| Boehringer Ingelheim | 4 | $70 |
| Sumitomo Pharma America, Inc. | 3 | $68 |
| Bayer | 3 | $62 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $56 |
| Dexcom, Inc. | 1 | $46 |
| Sanofi Pasteur Inc. | 2 | $45 |
| Medtronic | 1 | $37 |
| Corcept Therapeutics | 2 | $34 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $31 |
| Exact Sciences | 2 | $28 |
| Currax Pharmaceuticals LLC | 1 | $25 |
| Seqirus USA Inc | 1 | $20 |
| Neurelis, Inc. | 1 | $19 |
| Vanda Pharmaceuticals Inc. | 1 | $19 |
| Halozyme Inc | 1 | $19 |
| Antares Pharma, Inc. | 1 | $18 |
| Averitas Pharma Inc. | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Astellas Pharma US Inc | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,553 in reported general payments places this provider in the 85th percentile of 1,469 family medicine providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 115 | $94,100 |
| OzempicSemaglutide | 44 | $44,748 |
| JardianceEmpagliflozin | 43 | $41,331 |
| MyrbetriqMirabegron | 65 | $39,760 |
| XareltoRivaroxaban | 26 | $27,530 |
| RybelsusSemaglutide | 13 | $19,337 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 42 | $14,356 |
| TrulicityDulaglutide | 11 | $12,500 |
| MultaqDronedarone Hcl | 11 | $11,213 |
| Repatha SureclickEvolocumab | 11 | $9,283 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 13 | $8,869 |
| Tresiba Flextouch U-200Insulin Degludec | 13 | $7,800 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 12 | $7,557 |
| Spiriva RespimatTiotropium Bromide | 11 | $6,578 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 17 | $5,392 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Abrysvo, Paxlovid, Premarin | $945 | $105,183156 claims |
| Novo NordiskOzempic, Rybelsus | $674 | $64,08457 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $70 | $47,90954 claims |
| Astellas Pharma US IncMyrbetriq | $15 | $39,76065 claims |
| Johnson & JohnsonXarelto | $71 | $27,53026 claims |
| Lilly USA, LLCTrulicity | $627 | $12,50011 claims |
| GSKAnoro Ellipta, Shingrix | $193 | $12,48429 claims |
| Sanofi-aventis U.S. LLCMultaq | $13 | $11,21311 claims |
| AstraZenecaBreztri Aerosphere | $566 | $7,55712 claims |
| AbbVieSynthroid, Armour Thyroid | $941 | $5,04973 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,469 family medicine providers in Kansas.
Other family medicine in Manhattan
- Bradley HarrisonManhattan$314K
- Kent KiracofeManhattan$189K
- Kyle PlatzManhattan$51K
- Terry PolingWichita$24.2M
- Richard GloverNewton$19.6M
- Daniel DickersonLenexa$13.6M
- Patrick YaoOlathe$11.7M
- Michael RauschAugusta$8.1M
- Terry KleinWichita$5.9M
- Richard EgelhofWichita$4.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.